314 related articles for article (PubMed ID: 9733503)
1. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
[TBL] [Abstract][Full Text] [Related]
2. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
Millan MJ; Dekeyne A; Gobert A; Mannoury la Cour C; Brocco M; Rivet JM; Di Cara B; Lejeune F; Cremers TI; Flik G; de Jong TR; Olivier B; de Nanteuil G
Eur Neuropsychopharmacol; 2010 Sep; 20(9):599-621. PubMed ID: 20483567
[TBL] [Abstract][Full Text] [Related]
3. Reward for persistence in substance P research.
Wahlestedt C
Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
[No Abstract] [Full Text] [Related]
4. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
Lieb K; Fiebich BL; Berger M
Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
Adell A
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
7. Substance-P antagonists: a new treatment for depression?
Nutt D
Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
[No Abstract] [Full Text] [Related]
8. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
Rupniak NM
Curr Opin Investig Drugs; 2002 Feb; 3(2):257-61. PubMed ID: 12020057
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with substance P receptor (NK1) antagonists in depression.
Ranga K; Krishnan R
J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
[TBL] [Abstract][Full Text] [Related]
10. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
Hargreaves R
J Clin Psychiatry; 2002; 63 Suppl 11():18-24. PubMed ID: 12562139
[TBL] [Abstract][Full Text] [Related]
11. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.
Maubach KA; Martin K; Chicchi G; Harrison T; Wheeldon A; Swain CJ; Cumberbatch MJ; Rupniak NM; Seabrook GR
Neuroscience; 2002; 109(3):609-17. PubMed ID: 11823070
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
Rupniak NM; Carlson EC; Harrison T; Oates B; Seward E; Owen S; de Felipe C; Hunt S; Wheeldon A
Neuropharmacology; 2000 Jun; 39(8):1413-21. PubMed ID: 10818257
[TBL] [Abstract][Full Text] [Related]
13. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
14. Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs.
Boyce S; Smith D; Carlson E; Hewson L; Rigby M; O'Donnell R; Harrison T; Rupniak NM
Neuropharmacology; 2001 Jul; 41(1):130-7. PubMed ID: 11445193
[TBL] [Abstract][Full Text] [Related]
15. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
16. Can the placebo be the cure?
Enserink M
Science; 1999 Apr; 284(5412):238-40. PubMed ID: 10232967
[No Abstract] [Full Text] [Related]
17. Inhibition of substance P-induced defensive behavior via neurokinin-1 receptor antagonism in the central and medial but not basolateral nuclei of the amygdala in male Wistar rats.
Bassi GS; Carvalho MC; Almada RC; Brandão ML
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jul; 77():146-154. PubMed ID: 28390968
[TBL] [Abstract][Full Text] [Related]
18. Chronic psychosocial stress in tree shrews: effect of the substance P (NK1 receptor) antagonist L-760735 and clomipramine on endocrine and behavioral parameters.
van der Hart MG; de Biurrun G; Czéh B; Rupniak NM; den Boer JA; Fuchs E
Psychopharmacology (Berl); 2005 Sep; 181(2):207-16. PubMed ID: 15875166
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Hafizi S; Chandra P; Cowen J
Br J Psychiatry; 2007 Oct; 191():282-4. PubMed ID: 17906236
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
